Dr. Sanjay Gupta to Air Fifth Cannabis Documentary Focusing on CBD

September 25, 2019 15:00:43

This weekend, Dr. Sanjay Gupta is slated to air his fifth documentary on cannabis. This particular one focuses on cannabidiol (CBD) and is titled, “Weed 5: The CBD Craze.” It will air on CNN on Sunday (September, 2019).

In this documentary, Dr. Gupta will explore various aspects surrounding the CBD wave sweeping across not just the U.S. but most parts of the world as well. For example, he will investigate the THC levels in different CBD products on the market, as well as the presence of pesticides and other contaminants.

Dr. Sanjay Gupta, a neurosurgeon, works with CNN as its chief medical correspondent who is known for his program called “Vital Signs.” This isn’t the first time that Dr. Gupta is putting together a special report on cannabis.

In 2013, he released his first cannabis documentary titled, “Weed: Why I Changed My Mind About Marijuana.” In that first documentary on this subject, the neurosurgeon admits that he was opposed to using marijuana as a form of medicine, but his investigation showed that there was no scientific basis for classifying marijuana as a Schedule I substance. In contrast to the meaning of that classification, Gupta found there was a lot of evidence to show that marijuana not only had medical benefits, but it was sometimes the only medicine that could help some people. His report also showed that there was no scientific data to back the assertion that marijuana had a high potential for abuse.

In his second documentary (Weed 2: Cannabis Madness), Dr. Gupta focuses on the federal classification of marijuana and he comes to the conclusion that it was politics of pot working against the interests of patients.

In Weed 3: The Marijuana Revolution, Dr. Gupta delves deep into the available research done to prove the medicinal value of marijuana. He pays special attention to the work done on how to deal with post-traumatic stress disorder among veterans and on the research done by Dr. Sue Sisley. This documentary shows that scientific data exists to prove that marijuana indeed has medical benefits.

The forth documentary was titled “Weed 4: Pot vs. Pills” and it focuses on pain management. The doctor teamed up with an NFL superstar who used marijuana to overcome his addiction to prescription opioids. Dr. Gupta also covered what different marijuana advocates say about this substance and what they would like to see done by the federal government.

As you can see, Dr. Sanjay Gupta has done a lot to put discussions on marijuana in the mainstream media and experts believe that CBD industry insiders like Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) and Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) will be eager to watch what Gupta has put together this time round since it could exert some influence on the way the public views CBD.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office